Research on Parkinson's disease and its treatment. Covers mitochondrial protection, genetic progression markers, antibody therapies, and disease costs.
Researchers investigate how anxiety emerges and changes over the course of Parkinson's Disease, exploring its relationship to autonomic symptoms and brain regions like the amygdala. They aim to understand how functional changes in these areas may relate to behaviors.
Researchers developed an AI-based screening tool using pangrams to detect Parkinson’s disease with nearly 86 percent accuracy. The web-based test analyzes voice recordings for subtle patterns linked to the neurodegenerative disease, identifying potential warning signs.
Researchers developed a chemical probe that binds to damaged mitochondrial DNA, blocking enzymatic processes that lead to its degradation. This approach lessens mtDNA loss, preserving energy production in vulnerable tissues. The new molecule successfully reduced inflammation and maintained functional DNA despite chemical tagging.
Researchers now have access to high-value datasets that could transform our understanding of Parkinson’s and other neurodegenerative diseases. Data from 3 million human cells across 9 brain regions will help explore the brain at unprecedented resolution.
Scientists have discovered that microglia play a crucial role in regulating blood flow to the brain, and targeting them may improve blood flow deficits. The study suggests that restoring microglia function could prevent or reverse memory-stealing diseases caused by lack of adequate blood flow.
Researchers trained two dogs to distinguish between sebum swabs from people with and without Parkinson's disease, achieving sensitivity of up to 80% and specificity of up to 98%. The study suggests that dogs could help develop a quick, non-invasive method for early detection.
Scientists at University of South Australia developed a long-acting injectable formulation that delivers levodopa and carbidopa over a week, reducing the need for multiple daily tablets. The biodegradable formulation improves treatment outcomes and patient compliance, offering a potential game-changer for Parkinson's care.
Researchers found that Parkinson's disease symptoms on one side of the body can predict cognitive decline and psychiatric disorders. The study analyzed 80 studies to demonstrate the critical importance of personalized care tailored to individual disease profiles.
Non-invasive vagus nerve stimulation (nVNS) has demonstrated efficacy in reducing seizure frequency, improving mood, and enhancing motor recovery in various conditions. Future research should prioritize standardized protocols, large-scale trials, and biomarker development to personalize treatment.
A study by Universitat Oberta de Catalunya found that theatre-based interventions improve the emotional well-being of patients with Parkinson's, reducing depression and anxiety. Group activities foster emotional connections, increase empathy, and provide social support.
A new study led by Stanford Medicine suggests that inhibiting the LRRK2 enzyme could stabilize brain cell signaling and potentially halt cell death in Parkinson's disease. The researchers found that a kinase inhibitor, MLi-2, restored primary cilia on brain cells, enabling them to receive crucial signals and survive.
A new diagnostic tool uses AI to analyze handwriting signals, detecting subtle motor symptoms associated with Parkinson's disease. The device has shown an average accuracy of 96.22% in distinguishing patients from healthy individuals.
The new centre will investigate neural dynamics, developing novel interventions and devices to improve symptom relief and quality of life for people with brain disorders. It aims to harness neural dynamics for people with conditions like Parkinson’s disease or epilepsy.
Researchers used magnetoencephalography (MEG) technology to determine how levodopa affects brain signals in patients with Parkinson's disease. The study found that some patients experience 'off-target' effects of the drug, affecting brain regions beyond the intended dopamine-replacement therapy area.
Researchers identified hundreds of molecular markers in saliva associated with systemic pathological processes beyond the oral cavity. These markers can reflect genetic heritability of diseases such as prostate cancer, coronary disease, and Type 2 diabetes.
Researchers at the University of Sydney have identified a new brain protein involved in Parkinson's disease and found that targeting it with a drug treatment improved motor function in experimental models. The study suggests that this approach could slow or stop the progression of Parkinson's disease in humans.
Researchers analyzed single-cell transcriptomes from early, middle, and late stages of AD to identify subtle shifts in cellular activity. They found that mitochondria in vulnerable brain areas began to fail early in the disease, even before amyloid plaque buildup. The study also identified a gene called MEG3 involved in regulating mito...
Pernilla Wittung-Stafshede joins Rice University's Department of Chemistry as a professor, bringing expertise in metalloproteins and protein aggregation to enhance cancer research. Her focus is on understanding the role of copper-binding proteins in cancer metastasis and potential future therapies.
Scientists have identified four biomarkers in ear wax that may indicate Parkinson's disease, and an AI-based screening model can detect them with 94% accuracy. This technology could pave the way for earlier diagnosis and improved patient care.
Researchers at La Jolla Institute for Immunology discovered that T cell reactivity is highest during the prodromal period in Parkinson's disease, which can last for decades before noticeable symptoms. This finding may guide the development of early diagnostic tools and provide a new timeline for Parkinson's disease detection.
A study by King's College London found that specific changes in the microbiome are associated with cognitive decline in Parkinson's disease. The research suggests that oral-gut translocation may play an active role in worsening symptoms.
Researchers from the Mount Sinai Health System are presenting new studies on the impact of sleep on neurodegenerative diseases like Alzheimer's. The studies explore the relationship between obstructive sleep apnea and Alzheimer's pathogenesis, as well as the effects of sleep disruption on spatial learning and neuroinflammation.
Researchers at University of Virginia Health System discovered that an immune molecule called STING drives the formation of harmful plaques and protein tangles associated with Alzheimer's. Blocking STING protected lab mice from mental decline, suggesting a promising treatment target for neurodegenerative diseases.
A team of researchers from CRCHUM has identified a set of biomarkers in blood samples that could help diagnose Parkinson's disease. The study found that immune cells in the blood were activated and overexpressed genes associated with stress responses in patients with Parkinson's, forming a unique genetic signature.
A large-scale study from Karolinska Institutet reports that individuals with an autism diagnosis are four times more likely to develop early-onset Parkinson's disease. The researchers believe that shared underlying biological mechanisms may be at play, particularly involving the neurotransmitter dopamine.
Researchers discovered that specific neurons in the basal ganglia make precise decisions about when to allow and stop movements, licensing the timing of movement. This fine-grained movement control has important implications for understanding neurological disorders like Parkinson's disease.
Autophagy and lysosomal pathways orchestrate the unconventional secretion of PARK7, a PD-associated protein, in response to cellular stress. The study reveals a unique mechanism involving coordinated actions of macroautophagy and chaperone-mediated autophagy.
Davis Joseph's groundbreaking discovery identifies a common master switch that can cure multiple brain-related diseases with a single method. The unified theory establishes that regulating axon-based 4E-BP2 protein deamidation can control disease progression.
Researchers identified a dual learning system in the brain that enables habits to form and provides a scientific basis for breaking bad habits. The study suggests that replacing an action consistently can lead to the APE system forming a new habit, offering a potential strategy for overcoming addictions.
Researchers at Mass General Brigham have pinpointed a 'sweet spot' for focused ultrasound treatment to provide significant relief from essential tremor. The study identified a specific subregion of the brain's thalamus that can result in optimal and long-lasting tremor improvements while reducing side effects. With this breakthrough, p...
A team of researchers has discovered a small molecule that can selectively block cell death, which could lead to new treatments for neurodegenerative conditions. By targeting the killer protein BAX, the molecule can prevent excessive cell death in neurons, potentially slowing or halting disease progression.
A study found that exercise improves the maturation of transplanted stem cells and their integration with host neurons in a rodent model of Parkinson's disease. This enhancement is attributed to increased secretion of beneficial proteins in exercising rats, promoting transplant survival and function.
A new study reveals how a promising Parkinson's drug works by inhibiting the enzyme USP30, which prevents damaged mitochondria from being degraded. This breakthrough could lead to targeted therapies for Parkinson's disease and chronic kidney disease.
A study published in Neurology found that eating more ultra processed foods may speed up early signs of Parkinson's disease. Participants who consumed over 11 servings of ultra-processed food per day had a higher likelihood of developing three or more early symptoms of the disease.
A team of researchers has shown that it may be possible to diagnose Parkinson's disease years before it becomes untreatable by scanning people's brains with fMRI. The study used ultra-high field experimental MRI scanners and analyzed brain activity in response to sensory impairments such as loss of smell and visual deficits.
Researchers have found that promoting glucose metabolism in glial cells can relieve inflammation and photoreceptor degeneration in Alzheimer's patients. This discovery presents an exciting new therapeutic target for treating neurodegenerative conditions like Parkinson's.
Researchers at KAIST have identified a key mechanism behind neuroinflammatory responses in Parkinson's disease, which is regulated by an RNA editing enzyme called ADAR1. This discovery suggests that targeting this enzyme could serve as a novel therapeutic strategy for treating the disease.
Researchers from Université Laval discovered a non-invasive retinal exam can detect Parkinson's disease biomarkers, offering early diagnosis and potential intervention. The study found distinct retinal responses to light stimuli in people with Parkinson's compared to healthy individuals.
Researchers at UCSF found clinically significant improvements in mood, cognition, and motor function after psilocybin therapy for patients with mild to moderate Parkinson's disease. The study suggests that psilocybin could provide relief from multiple symptoms of the disease by reducing inflammation and promoting neuroplasticity.
Researchers developed promising α-synuclein PET tracers that can visualize protein aggregates in living patients, enabling earlier diagnosis and treatment monitoring. Tracers like [18F]C05-05 and [18F]ACI-12589 showed significant results in distinguishing synucleinopathies from healthy controls.
Researchers discovered that the brain suppresses the current action without using another mechanism to inhibit it, enabling seamless transitions between actions. This finding could lead to the development of biologically-inspired robotic systems and improve clinical treatments for Parkinson's patients.
A misfolded protein in spinal fluid facilitates reliable Parkinson's diagnosis even in its early stages. The biomarker has a sensitivity and specificity of over 90%, making it a promising tool for disease management and potential therapy development.
Researchers found that ATP regulates protein condensation and cytoplasm viscosity, preventing harmful protein aggregates. Boosting ATP production decreases viscosity, dispersing existing and preventing future protein aggregations.
A phase 1 clinical trial found that nerve cells derived from embryonic stem cells can produce dopamine, a chemical lacking in Parkinson's patients. The treatment has been licensed to BlueRock Therapeutics and is expected to proceed to a larger patient group in the first half of 2025.
Dr. Rhonda Winegar investigates the effectiveness of music therapy in supporting neurological care, including its ability to reduce anxiety and depression in Alzheimer's patients. Her research also highlights its potential to regulate heart rate and blood pressure, as well as improve motor function in individuals with Parkinson's disease.
A novel AI tool, RibbonFold, predicts the structures of amyloids, revealing previously overlooked nuances in their formation and evolution. This breakthrough may reshape how researchers approach neurodegenerative disease treatment and offers a scalable method for analyzing harmful protein aggregates.
A University of Florida researcher has developed a groundbreaking AI tool called VisionMD that analyzes videos of patients with Parkinson's disease and other movement disorders. The tool provides valuable information about how the disease is progressing and responding to medications, improving patient care and advancing clinical research.
Dr. J. Timothy Greenamyre is awarded the 2025 Jay Van Andel Award for his pioneering research into gene-environment interactions and its improved understanding of Parkinson's development and progression. The award highlights his work on mitochondria, LRRK2, and pesticide exposure risks in Parkinson's disease.
Researchers will examine the link between cellular senescence and Parkinson's disease onset and progression. The team aims to find new ways to slow disease progression and establish senescence as a novel target for treatment.
Researchers developed a simple, cost-effective blood test that detects Parkinson's disease long before symptoms emerge by analyzing transfer RNA fragments. The test has an accuracy surpassing existing clinical diagnostic tools and may alleviate uncertainty faced by patients and clinicians.
Researchers used CRISPR interference to examine every gene in the human genome and discovered a new set of genes contributing to Parkinson's disease risk. The study identified the Commander complex, which regulates lysosomal function and is implicated in PD risk, offering opportunities for new treatments.
A small protein involved in neurodegeneration leading to Parkinson's disease also drives a type of skin cancer known as melanoma, according to new research. The study suggests new avenues for drug development to reduce the risk of developing both diseases by targeting alpha-synuclein.
Researchers investigated the neuroregenerative potential of 5-NOT and Epi, discovering they protected SH-SY5Y cells from MPP+ toxicity by regulating key proteins. The findings support 5-NOT as a glycomimetic drug candidate for Parkinson's disease treatment.
A new study by the University of Turku found that up to one in six Parkinson's disease diagnoses are later corrected, with most changes occurring within two years. The study highlights the challenges of distinguishing Parkinson's disease from other similar disorders and emphasizes the need for improved diagnostic processes and training.
Researchers at Johns Hopkins Medicine have discovered how a group of proteins linked to Parkinson's and ALS act as 'guardians' of mitochondria, maintaining their normal size and function. The study found that when mitochondria become too large, they leak mitochondrial DNA into the cytosol, triggering an inflammatory response.
A new study found that a harmful build-up of the alpha-synuclein protein in nerve clusters near the heart may contribute to Parkinson's-related cardiac autonomic dysfunction. This suggests that targeting toxic protein clumps outside the brain could help manage symptoms and quality of life for people with Parkinson's.
Researchers at Temple University have discovered a new way to block the enzyme DLK, which plays a key role in neurodegenerative diseases. The breakthrough approach protects damaged neurons while preserving healthy neuron function.
A new study suggests AI-driven smart devices can revolutionize healthcare by detecting cardiac issues early, triggering emergency responses. The Internet of Medical Things (IoMT) technology enables real-time patient monitoring and analysis, improving efficiency and reducing costs.
Researchers at UT Health San Antonio are among the first to use adaptive deep brain stimulation technology that adjusts treatment based on a patient's symptoms. This innovative approach offers improved therapy and symptom optimization for patients with Parkinson's disease, dystonia, epilepsy, and essential tremor conditions.
Researchers have developed a new strategy to target hard-to-target proteins in human cells by reprogramming proteases to selectively degrade disease-causing proteins. The study demonstrates proof of concept for developing novel therapies for Parkinson's disease, cancers, and other illnesses, using α-Synuclein as a model protein.